Researchers on Friday presented detailed investigations into a gene therapy death that sparked fear and uncertainty last year among scientists who felt they had been approaching powerful treatments for a long list of brain diseases.
The researchers did not conclude precisely what led to the patient’s death but proposed experiments to screen future therapies.
“What I want everyone to take home is: I think we’re starting to build a framework for testing this,” said Nicholas Flytzanis, chief research and innovation officer at Capsida Biotherapeutics. “I think it can be tested, and I think this specific novel risk is one that we can try to mitigate and predict in the future.”
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Source: www.statnews.com



